Radiko Holding Completes Its Transaction With BioNeva

Radiko Holdings, a leading cannabis-focused company, has announced on Monday May 11, 2020 that the company has successfully completed its transaction with Nevada-based BioNMeva Innovations of Carson City.

According to the details released by the company, BioNeva is a leading cannabis cultivator that holds cannabis cultivation licenses of both recreational and medical marijuana. The company has got the fully operational facility of one acre of leased land from outside and 8,250 f ft2 for indoor cannabis cultivation. The facility is equipped with the highly efficient auxiliary lighting systems, roof glazing material can canopy of 4,000 ft2.

Chief Executive Officer of the Radiko Holdings, Steve Gormley said, “This transaction adds significant enterprise value, and furthers our corporate development strategy of acquiring select, highly-profitable value chain investments to facilitate brand growth, enhance margins and bolster cash flow. We appreciate the patience of our shareholders as we worked to finalize this transaction amid COVID-19, and we look forward to reporting our progress as we execute our plan.”

Holder and Director of BioNeva Innovations of Carson City, Bob Yosaitis said, “I am extremely pleased that Radiko and BioNeva are able to join forces and create broader opportunities for both organizations. The Radiko team has extensive cannabis experience and the expertise to build successful operations for both the Carson City [BioNeva] and Washoe locations, and the addition of cultivation should contribute significantly to overall earnings and provide a valuable platform for Radiko’s portfolio of brands.”

About Radiko Holdings:

Radiko Holdings is a cannabis-focused company that offers the best commercial products to compliment the consumer’s lifestyles. The company’s mission is to market and build a wide range of cannabis-based products to support EBITDA. The company markets its products with permitted THC content for medical and recreational use.

Nuvo Pharmaceuticals Announced Q1 2020 Financial Results

Nuvo Pharmaceuticals, a Canada-based leading healthcare company featuring a wide range of commercial products, has announced the Q1 2020 financial results of the company on Monday May 11, 2020. According to the details released by the company, the total revenue of the company increased up to 11% and stood at 18.9 million USD, as compared to 17.1 million USD for the previous three months.

The company’s two commercial products Cambia and Blexton have collected total revenue up to 6.0 million USD, which has increased 94$ as compared to the past three months.

The company has further said that it had made the principal loan payment of 11.5 million USD in the three months ended March 31, 2020.

The adjusted EBTIDA of the company stood at 8.0 million USD, which increased up to 52% as compared to the past three months ended March 31, 2020.

Chief Executive Officer and President of Nuvo Pharmaceuticals, Jesse Ledger said, “The COVID-19 pandemic has been the overriding focus of the world over the last couple of months. During this time, Nuvo continues to operate as an essential business. We have made necessary changes so we can continue to operate and supply our healthcare products to global partners, wholesalers, pharmacies, and ultimately patients, while ensuring our employees remain safe and healthy.”

“Despite the challenges presented by the COVID-19 pandemic, we are making progress in achieving a number of anticipated milestones in the second quarter, including the launch of Resultz in Germany and the submission of the Blexten pediatric dossier to Health Canada, and we continue to prepare for the Canadian commercial launches of Suvexx and Neovisc Plus and Neovisc One later this year. Furthermore, Blexten and Cambia continued their strong performance in the first quarter,” Jesse Ledger further added.

Ellis Island Honors Society Speeds Up Covid-19 Relief Activities

Ellis Island Honors Society or EIHS, a leading US-based organization with a mission to foster tolerances and preserve cultural diversity among ethnic groups, has announced on Friday May 1, 2020 that the company is speeding up the Covid-19 relief efforts by fundraising campaign for healthcare provider and medical centers, which are worst affected by the pandemic.

According to the PR Newswire News Agency, the fundraising campaign was started by the Combat Go and Black Belt Magazine. These two companies help to launch the virtual martial arts magazine, Fight Back, featuring World’s leading Martial Artists.

Ellis Island Honors Society (EIHS) is registered as the non-profit organization and it will help to raise the funds, as 100% amount of the donated amount would be going to the American Red Cross to speed up Covid-19 relief activities.

Chairman of Ellis Island Honors Society (EIHS), Nasser Kazeminy said, “My heart and prayers go out to all who are suffering through this crisis or providing care for loved ones who are afflicted.”

“And my greatest respect to those volunteering in service to others. This is the time to stand together, under one flag, and do what we can to help America and our fellow citizens,” Nasser Kazeminy further said.

Co-Founder and Chief Executive Officer of Jungo TV and Former Martial Arts Champion, George Chung said, “During these uncertain times, it gives us hope to see how people all over the world are finding new and innovative ways to stay connected.”

“We are honored to be part of this global martial arts experience Fight Back with our partners Black Belt Magazine, Bellator, and Ellis Island Honors Society to support the American Red Cross in the global fight to end COVID-19,” CEO of Jungo TV George Chung further added.

Stroke Surgeons Kicks Off National Stroke Awareness Month With Plea For Vigilance Amid The Covid-19 Pandemic

As the connection of stroke and Covid-19 pandemic is growing, its even more necessary to immediately inform the emergency number to treat the stroke rather than waiting to turn the stroke into a pandemic. This guidance is given by the Stroke Surgeons during kicking of the National Stroke Awareness Month. Furthermore, the Stroke Surgeons plead to ensure maximum social distancing during the ongoing Covid-19 pandemic.

It is a fact that stroke can lead to the long-term disability and even the patient in the normal conditions. Each year, more than 800,000 US people suffer from the stroke and about 140,000 people losé their lives due to it along with many more left disabled for the rest of their lives. Prominent Stroke Surgeons have said that there is a high probability that the US might get record a number of stroke-related death due to the ongoing Covid-19 pandemic.

Prominent Stroke Surgeon of Mount Sinai Hospital in Newyork, Dr. J Mocco said, “The connection between COVID-19 and stroke is real. After an initial drop in stroke cases in the time leading up to surge, the number of stroke patients doubled during the COVID-19 peak and more than half were COVID-19 positive. What’s more, these patients were on average 15 years younger than typical stroke patients and among the least likely to otherwise have a stroke.”

A prominent Stroke Surgeon with UW Medicine in Seattle, Dr. Michael Levitt said, “Patients should know that stroke units in hospitals are taking every precaution to protect our patients and our staff from COVID-19 exposure.”

“What remains unchanged throughout this pandemic is that we still need to play it safe when it comes to stroke and always call 9-1-1. Avoiding or delaying treatment will only lead to more deaths,” Dr. Michael Levitt further added.

Eye Catching Stock News: PTC Therapeutics (NASDAQ:PTCT)

PTC Therapeutics (NASDAQ:PTCT)  stock identified change of 61.66% away from 52-week low price and recently located move of -16.88% off 52-week high price. It has market worth of $3.03BM. PTCT stock has been recorded 2.27% away from 50 day moving average and 9.68% away from 200 day moving average. Moving closer, we can see that shares have been trading 14.34% off 20-day moving average.

On April 17, 2020, PTC Therapeutics (NASDAQ:PTCT) notified the appointments of Matthew Klein, M.D., to Chief Development Officer and Eric Pauwels to Chief Business Officer. Dr. Klein will be responsible for the development of our clinical stage programs. As the Chief Business Officer, Mr. Pauwels will be responsible for our customer facing activities with health care providers, patients and payers ensuring that our therapies are available and accessible to rare disease patients and their families worldwide.

I am very pleased to announce these well-deserved appointments to PTC’s Executive Committee, said Stuart Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics Matt and Eric are both recognized industry leaders with demonstrated track records of success. In their new roles, they will continue to advance our development pipeline, fuel our company’s growth and deliver on our mission to develop and provide transformative therapies for patients living with rare disorders.

Dr. Klein joined PTC last year as Global Head of Gene & Mitochondrial Therapies after serving as Chief Executive Officer and Chief Medical Officer of BioElectron Technology Corporation, certain assets of which were acquired by PTC in 2019. Prior to leading BioElectron, Dr. Klein was the Auth-Washington Research Chair of Restorative Burn Surgery at the University of Washington. Dr. Klein holds a Bachelor of Arts in History, and graduated summa cum laude and phi beta kappa from the University of Pennsylvania in Philadelphia, Pennsylvania and a Doctor of Medicine from Yale University School of Medicine in New Haven, Connecticut.

The Healthcare sector company, PTC Therapeutics noticed change of 4.82% to $49.78 along volume of 953191 shares in recent session compared to an average volume of 973.03K. The stock observed return of 9.58% in 5 days trading activity. The stock was at 34.47% over one month performance. PTCT’s shares are at -5.13% for the quarter and driving a 40.54% return over the course of the past year and is now at 3.64% since this point in 2018.

The average volatility for the week at 4.85% and for month was at 8.22%. There are 60.87M shares outstanding and 60.65M shares are floated in market. Right now the stock beta is 1.54.

Cognizant Technology Solutions Corporation (NASDAQ:CTSH) announces updates in response to the impact of the novel coronavirus (COVID-19)

Cognizant Technology Solutions Corporation (NASDAQ:CTSH) is now trading -27.41% off 52-week high price. On the other end, the stock has been noted 35.67% away from the low price over the last 52-weeks. The stock changed 5.62% to recent value of $54.28. The stock transacted 6155119 shares during most recent day however it has an average volume of 4.66M shares. The company has 559.89M of outstanding shares and 547.33M shares were floated in the market.

On April 9, 2020, Cognizant Technology Solutions Corporation (NASDAQ:CTSH) one of the world’s leading professional services companies, reported certain updates in response to the impact of the novel coronavirus (COVID-19) on business operations.

Our priorities remain the health and safety of our associates and the business continuity of our clients, said Brian Humphries, Chief Executive Officer. We are committed to helping our clients as they navigate unprecedented business challenges as well as supporting the efforts of governments globally to contain the spread of the virus.

I am pleased with our business momentum in the first two months of the quarter and grateful for the dedication and professionalism of our associates in March, both of which enabled us to meet our previously announced revenue guidance. We acted decisively to limit COVID-19’s impact on our business, including rapidly enabling work-from-home capabilities across our delivery teams. We will continue to take steps to protect our associates and support the evolving needs of clients in ‘s environment.

In this fluid environment where uncertainty prevails, we are well-positioned with deep client relationships across more than a dozen industries, and a strong balance sheet that provides solid financial flexibility. As ever, we stand committed to help our clients manage through economic, technological and other disruptions through our innovative solutions and talented associates, Humphries continued. I am proud of our 292,000 associates who have risen to the challenge of serving our clients with empathy, initiative and courage, and confident that we will emerge from this global crisis stronger together.

Its earnings per share (EPS) expected to touch remained -8.40% for this year while earning per share for the next 5-years is expected to reach at 7.96%. CTSH has a gross margin of 36.60% and an operating margin of 14.60% while its profit margin remained 11.00% for the last 12 months.

According to the most recent quarter its current ratio was 2.6 that represents company’s ability to meet its current financial obligations. The price moved ahead of 15.83% from the mean of 20 days, -5.17% from mean of 50 days SMA and performed -11.20% from mean of 200 days price. Company’s performance for the week was 22.56%, 2.15% for month and YTD performance remained -12.48%.

Notable News to Watch: Centene Corporation (NYSE:CNC)

Centene Corporation (NYSE:CNC)spotted trading -12.41% off 52-week high price. On the other end, the stock has been noted 44.43% away from the low price over the last 52-weeks. The stock changed 10.11% to recent value of $60.12. The stock transacted 4361869 shares during most recent day however it has an average volume of 6.60M shares. The company has 605.73M of outstanding shares and 575.77M shares were floated in the market.

On April 6, 2020, Centene Corporation (NYSE:CNC) released that it is establishing a Medical Reserve Leave policy to support clinical staff who want to join a medical reserve force and serve their communities, during the COVID-19 pandemic. The policy will support clinical staff by providing paid leave and benefits for up to three months of volunteer service.

Our employees have a deep commitment to take care of their communities in times of need and we will always support their passion to serve, said Michael Neidorff, Chairman, President and CEO of Centene. Our medical reserve leave policy will ensure our clinical staff are paid and that their benefits are protected during their time of service.

If an employee decides to take advantage of the medical reserve leave benefit, they will:

  • Maintain pay in accordance with the number of hours regularly scheduled to work;
  • Maintain enrolled benefit coverage as an active employee;
  • Continue to accrue paid time off; and
  • Maintain eligibility for holiday pay for any holidays that occur during the time of service.

Its earnings per share (EPS) expected to touch remained 39.10% for this year while earning per share for the next 5-years is expected to reach at 13.63%. CNC has a gross margin of 17.80% and an operating margin of 2.30% while its profit margin remained 1.80% for the last 12 months.

According to the most recent quarter its current ratio was 1.6 that represents company’s ability to meet its current financial obligations. The price moved ahead of 8.75% from the mean of 20 days, 1.36% from mean of 50 days SMA and performed 10.36% from mean of 200 days price. Company’s performance for the week was 4.18%, 2.66% for month and YTD performance remained -4.37%.

BMO Financial Group (NYSE:BMO) completed the acquisition of Clearpool Group

BMO Financial Group (NYSE:BMO) stock observed trading -37.46% off 52-week high price. On the other end, the stock has been noted 30.49% away from low price over the last 52-weeks. The stock disclosed a move of -21.16% away from 50 day moving average and -30.35% away from 200 day moving average. Moving closer, we can see that shares have been trading 6.43% off 20-day moving average. It has market cap of $32.46B and dividend yield of 6.38%.

On April 6, 2020, BMO Financial Group (NYSE:BMO) reported that it has completed the acquisition of Clearpool Group, a New York-based provider of holistic electronic trading solutions and an independent agency broker-dealer operating in the U.S. and Canada.

BMO announced the acquisition on January 22, 2020. The transaction delivers powerful new capabilities to BMO’s electronic trading platform. As the nature of equity trading shifts to increased emphasis on electronic trading, the acquisition of Clearpool demonstrates BMO’s commitment to delivering leading edge trading technology to its global client base.

Clearpool continues to be a separate broker-dealer with information barriers to secure clients’ confidential information.

The acquisition is not expected to have a significant impact on the financial results of the bank and will reduce CET1 ratio by approximately 10bps.

In connection with the transaction, BMO Capital Markets acted as financial advisor and Debevoise & Plimpton LLP and Osler, Hoskin & Harcourt LLP acted as legal counsel to BMO.  Financial Technology Partners acted as financial advisor and Morgan, Lewis, & Bockius LLP, Murphy & McGonigle and Stikeman Elliott LLP acted as legal counsel to Clearpool.

The Canada based company Bank of Montreal moved with change of 5.53% to $49.99 with the total traded volume of 822354 shares in recent session versus to an average volume of 925.55K. The stock was observed in the 5 days activity at 4.43%. The one month performance of stock was -20.58%. BMO’s shares are at -35.51% for the quarter and driving a -34.58% return over the course of the past year and is now at -35.50% since this point in 2018.  Right now the stock beta is 1.25. The average volatility for the week and month was at 4.69% and 8.10% respectively. There are 649.39M shares outstanding and 639.22M shares are floated in market.

Stock News Buzz: Dorchester Minerals, L.P. (NASDAQ:DMLP)

Dorchester Minerals, L.P. (NASDAQ:DMLP) changed 0.32% to recent value of $9.38. The stock transacted 44213 shares during most recent day however it has an average volume of 128.43K shares. It spotted trading -56.29% off 52-week high price. On the other end, the stock has been noted 10.09% away from the low price over the last 52-weeks.

On April 3, 2020, Dorchester Minerals, L.P. (NASDAQ:DMLP) released that, due to the emerging public health impact of the COVID-19 (Coronavirus) pandemic, the date, time and location and format of its 2020 Annual Meeting of Limited Partners (the 2020 Annual Meeting) has been changed to 2:00 p.m. Central Time on Monday, May 18, 2020, and from an in-person meeting to a virtual meeting. Unitholders may not attend the meeting in person.

On April 2, 2020, the Partnership’s Board of Managers (the Board) approved the change to the date, time, location and format of the 2020 Annual Meeting in support of the health and well-being of the Partnership’s employees, unitholders and other associates, as well as the related protocols that have been or may be imposed by federal, state and local governments.

Unitholders of record at the close of business on March 19, 2020 will be able to access the 2020 Annual Meeting webcast at www.virtualshareholdermeeting.com/DMLP2020. Unitholders who attend the virtual meeting with their 16-digit control number as identified on their proxy card or their voting instruction form, will have the same rights and opportunities to participate as they would at an in-person meeting. Unitholders issued a voting instruction form that does not contain a 16-digit control number will still be able to attend the 2020 Annual Meeting as a guest and listen to the proceedings but must contact their brokerage firm, bank, or other financial institution for instructions on how to vote at the 2020 Annual Meeting. All Unitholders may continue to cast their votes for the 2020 Annual Meeting at www.proxyvote.com until 11:59 p.m. Eastern Time the day before the cut-off date or meeting date and in accordance with the instructions in the Partnership’s proxy materials. Registered Unitholders may also submit questions for the 2020 Annual Meeting at [email protected] until 11:59 p.m. Eastern Time five days prior to the date of the 2020 Annual Meeting.

DMLP has a gross margin of 91.60% and an operating margin of 67.00% while its profit margin remained 64.80% for the last 12 months. Its earnings per share (EPS) expected to touch remained -7.10% for this year.

The company has 35.97M of outstanding shares and 31.55M shares were floated in the market. According to the most recent quarter its current ratio was 12 that represents company’s ability to meet its current financial obligations. The price moved ahead of -9.69% from the mean of 20 days, -31.86% from mean of 50 days SMA and performed -45.45% from mean of 200 days price. Company’s performance for the week was 3.19%, -32.95% for month and YTD performance remained -51.92%.

Notable News to Focus: Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) stock observed trading -35.33% off 52-week high price. On the other end, the stock has been noted 14.80% away from low price over the last 52-weeks. The stock disclosed a move of -20.78% away from 50 day moving average and -25.25% away from 200 day moving average. Moving closer, we can see that shares have been trading -5.91% off 20-day moving average. It has market cap of $5.82B.

On March 31, 2020, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) provided an update regarding the impact of COVID-19 on its business and the actions it is taking to mitigate the spread of this virus.

Jazz provides essential medicines to patients around the world and we are committed to delivering on this important mission.  We have implemented a robust continuity plan to address the impact of COVID-19 on our business.  We are highly focused on ensuring patients have access to our medicines and protecting the health and safety of our employees and the communities in which we operate, said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals.  The company is in a strong financial position, having entered the year with over $1 billion in cash and investments and access to significant additional liquidity.  Our financial strength prepares us to navigate through this pandemic while continuing to execute on our key strategic objectives to support our long-term growth.

Jazz sees a limited financial impact, given its portfolio of differentiated products addressing chronic and life-threatening diseases. However, given the global economic slowdown, reduced field-based interactions with healthcare professionals and the uncertainty surrounding the scale and duration of the pandemic, the company, at this time, cannot rule out future impact on its business and associated guidance.  Jazz expects to provide an update on all key business areas during its first quarter 2020 financial results in early May.

The Ireland based company Jazz Pharmaceuticals plc moved with change of 0.14% to $99.74 with the total traded volume of 709472 shares in recent session versus to an average volume of 679.93K shares. The stock was observed in the 5 days activity at 4.31%. The one month performance of stock was -20.28%. JAZZ’s shares are at -32.90% for the quarter and driving a -30.22% return over the course of the past year and is now at -33.19% since this point in 2018.  Right now the stock beta is 1.29. The average volatility for the week and month was at 5.29% and 8.23% respectively. There are 58.32M shares outstanding and 54.56M shares are floated in market.